France
Inato, founded in 2016, is revolutionizing the clinical trial industry by matching research sites to the appropriate protocols, thereby unlocking potential globally. Based in France, the company aims to democratize access to clinical trials, ensuring wider participation beyond the 5% of sites handling the majority of trials.
Their innovation lies in a platform that connects pharmaceutical giants with a diverse range of research sites. This not only facilitates trial accessibility but also enhances site performance and patient reach. With AI and Machine Learning at its core, Inato's platform supports community sites at no charge, enabling broader and more diverse trial participation.
In a recent funding round on 29 March 2023, Inato secured a $20.00M Series A investment from notable investors, including Cathay Innovation, Obvious Ventures, Lamaison Partners, and Top Harvest Capital. Inato represents a promising opportunity in the Health Care and Pharmaceutical sectors, poised to expedite drug development and enhance trial inclusivity.
